Pyriform sinus squamous cell carcinoma: oncological outcomes in good responders of induction chemotherapy-based larynx preservation protocols

被引:0
作者
Zacharias Vourexakis
Anne-Marie Le Ridant
Pavel Dulguerov
François Janot
机构
[1] Institut Gustave Roussy,Department of Head and Neck Surgery
[2] University Hospital of Geneva and University of Geneva School of Medicine,Department of Otolaryngology
来源
European Archives of Oto-Rhino-Laryngology | 2015年 / 272卷
关键词
Pyriform sinus; Chemosensitive; Responders; Radiation therapy; Survival;
D O I
暂无
中图分类号
学科分类号
摘要
Induction chemotherapy-based larynx preservation protocols use chemotherapy to select exclusively patients with ‘chemosensitive’ tumors for a nonsurgical treatment with radiation therapy. This study on pyriform sinus squamous cell carcinoma (SCC) is interested in the oncological outcome of treatment based on radiation therapy when offered to patients with tumors responding to induction chemotherapy. This was a retrospective cohort study. The cohort included good responders to induction chemotherapy, subsequently treated with definite radiation therapy (with or without concomitant chemotherapy) for pyriform sinus SCC, in a tertiary referral cancer center. The primary endpoints were overall, laryngectomy-free and disease-free survival and the secondary endpoints were analysis of treatment failures and possibilities of salvage treatment. Forty-two patients fulfilled the inclusion criteria and were retained for analysis; 7 % were stage II (3/42), 48 % stage III (20/42) and 45 % stage IV (19/42). At 1, 3 and 5 years, the overall survival was 95 % (40/42), 74 % (31/42), and 60 % (SE ≈ 0.08), respectively. For the same intervals, the laryngectomy-free survival was 90 % (38/42), 69 % (29/42) and 50 % (SE ≈ 0.08), respectively. The estimated 5-year disease-free survival was also 50 %. Disease-free survival was significantly better for N0 patients. There was a 28 % recurrence rate, mainly in the primary tumor site (9/11), with or without simultaneous nodal recurrence. Interestingly, more than one-third of all oncologic failures occurred beyond the first 3 years of follow-up. Salvage treatment was not possible or definitely inefficient in at least 2/3 of all recurrences. In candidates for larynx preservation for a pyriform sinus SCC, good response to induction chemotherapy followed by definite radiation therapy seems to be associated with a more favorable prognosis. Nevertheless, in case of locoregional recurrence the possibilities for efficient salvage treatment are limited.
引用
收藏
页码:1725 / 1731
页数:6
相关论文
共 66 条
[1]  
Lefebvre JL(2009)Larynx preservation consensus panel. Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary Head Neck 31 429-441
[2]  
Ang KK(1991)Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer N Engl J Med 324 1685-1690
[3]  
Forastiere AA(2003)Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer N Engl J Med 349 2091-2098
[4]  
Goepfert H(1996)Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group J Natl Cancer Inst 88 890-899
[5]  
Maor M(2010)Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma Acta Otolaryngol 130 150-155
[6]  
Lefebvre JL(2004)Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer N Engl J Med 350 1945-1952
[7]  
Chevalier D(1997)Hypopharyngeal cancer patient care evaluation Laryngoscope 107 1005-1017
[8]  
Luboinski B(1998)Randomized trial of induction chemotherapy in larynx carcinoma Oral Oncol 34 224-228
[9]  
Kirkpatrick A(1995)Laryngeal preservation for advanced laryngeal and hypopharyngeal cancers Arch Otolaryngol Head Neck Surg 121 219-223
[10]  
Collette L(1996)Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer Head Neck 18 405-411